Quality Improvement Grant Program: Treatment Patterns of CDK 4/6 Inhibitor Utilization in HR+/HER2- Metastatic Breast Cancer

Funding Agency:
Pfizer Inc.

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP.

The use of cyclin dependent kinase (CDK) 4/6 inhibitors in combination with endocrine therapy in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) has demonstrated improved progression free survival (PFS) across landmark trials relative to endocrine therapy alone.

Guidelines recommend CDK 4/6 inhibitors in combination with endocrine therapy for the treatment of women with HR+/HER2- MBC.

Quality Improvement (QI) is a cyclic process of systematic, data-guided activities designed to bring about immediate, positive changes in the delivery of healthcare in specific settings. The Commission on Cancer (CoC) as well as the Quality Oncology Practice Initiative (QOPI) endorse utilizing data for continuous quality improvement as well as using nationally recognized guidelines to drive treatment selection.

The intent of this QI RFP is to support cancer care facilities interested in identifying and reducing unwarranted variations and/or disparities in care by: - Exploring utilization patterns of CDK 4/6 inhibitors for the treatment of HR+/HER2- MBC - Implementing process improvement intervention(s) to address identified issues

Examples of variations in care that might be examined include treatment patterns across multiple affiliated sites, geographic differences, ethnicity- or age-related biases. Each grant recipient and their QI team can decide which aspect(s) of quality-care-improvement to address once the data analysis stage is complete.

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. Information on how to submit requests for support of clinical research projects can be found at www.Pfizer.com/isr.

Grant Application due date: November 4, 2019

Agency Website

Eligibility Requirements

Geographic Scope United States only

• The types of organizations eligible for this RFP are listed in the Target Audience section below. • If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. All institutions must have a relevant role and the requesting organization must have a key role in the project. • For projects offering continuing education credit, the requesting organization must be accredited. 

Target Audience: Cancer care facilities including community cancer centers, hospitals, healthsystems, comprehensive cancer centers, and networks of oncology clinics. Individual physician-owned practices are not eligible



Amount Description

• Individual projects requesting up to $100,000 will be considered. The estimated total available budget related to this RFP is $1 million. • Grant funds can be used for project management costs, data analysis costs, QI team activities, technology-based enhancements, professional or patient education, process improvement implementation costs etc. Grant funds cannot be used to cover the costs of patient-care delivery or medications.

Funding Type





Medical - Clinical Science
Social Sciences

External Deadline

November 4, 2019